Cortical bone size deficit in adult patients with type 1 diabetes mellitus by Verroken, Charlotte et al.
C L I N I C A L R E S E A R C H A R T I C L E
Cortical Bone Size Deficit in Adult Patients With
Type 1 Diabetes Mellitus
Charlotte Verroken,1,2 Wout Pieters,1,2 Loı¨c Beddeleem,1,2 Stefan Goemaere,1
Hans-Georg Zmierczak,1 Samyah Shadid,2 Jean-Marc Kaufman,1,2
and Bruno Lapauw1,2
1Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, 9000 Ghent, Belgium; and
2Department of Endocrinology, Ghent University Hospital, 9000 Ghent, Belgium
Context: The increased fracture risk associated with type 1 diabetes mellitus (T1DM) remains un-
explained by traditional risk factors such as low areal bone mineral density (aBMD). Nonetheless,
few data exist on other determinants of bone strength in T1DM, including volumetric bonemineral
density (vBMD) and bone geometry.
Objective:We compared areal and volumetric bone parameters and cortical bone geometry in adult
T1DM patients and sex- and age-matched controls.
Design: Cross-sectional study including 64 adult T1DMpatients (38men;mean age, 41.16 8.1 years)
and 63 sex- and age-matched controls.
Main Outcome Measures: Areal bone parameters using dual-energy X-ray absorptiometry;
volumetric bone parameters and cortical bone geometry using peripheral quantitative
computed tomography.
Results: T1DMwas associatedwith lower aBMDat the total body, femoral neck, and total hip; lower
trabecular vBMD at the distal radius; and higher cortical but lower total vBMD at the radial shaft. In
addition, subjects with T1DM had a similar periosteal but larger endosteal circumference, smaller
cortical thickness, and lower cortical over total bone area ratio. Differences in bone parameters
could not be explained by differences in bone turnover markers or body composition, but cortical
area was inversely associated with glycemic variability and long-term glycemic control.
Conclusions: Besides decreased aBMDand trabecular vBMD, adult T1DMpatients presentwith a cortical
bone size deficit, which may contribute to their increased fracture risk. This deficit is mainly situated at
the endosteal envelope, suggesting imbalanced remodeling rather than compromised modeling pro-
cesses as the underlying mechanism. (J Clin Endocrinol Metab 102: 2887–2895, 2017)
Osteoporosis and its related fractures remain a majorhealth problem, leading to increased morbidity and
mortality in both men and women. Besides conditions
such as rheumatoid arthritis and hypogonadism, type 1
diabetes mellitus (T1DM) is now recognized as another
risk factor for developing osteoporosis. Indeed, the
overall fracture risk in subjects with T1DM has been
estimated to be about threefold higher than in a general
population (1), whereas their risk of hip fractures is about
sevenfold increased compared with nondiabetic subjects
(2, 3). Moreover, the observed fracture incidence in
patients with T1DM is much higher than expected based
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on their moderately reduced areal bone mineral density
(aBMD) (3), suggesting that other factors might be re-
sponsible for the increased fracture risk in T1DM. On
the one hand, certain indirect factors may play a role,
including an increased fall risk because of diabetic
complications and treatment-induced hypoglycemia.
On the other hand, T1DM may be associated with an
increased bone fragility which is not entirely captured by
traditional dual-energy X-ray absorptiometry (DXA)
measurements.
Besides by bone mass, the strength of a bone is im-
portantly determined by its material and structural
properties. However, data on these parameters in subjects
with T1DM are scarce and inconclusive. Deficits in
trabecular microarchitecture were reported in adult
women with childhood-onset T1DM using magnetic
resonance imaging (MRI) at the proximal tibia (4), and in
T1DM patients with microvascular disease (MVD) using
high-resolution peripheral quantitative computed to-
mography (HR-pQCT) at the ultradistal radius and tibia
(5), whereas another study found no differences in his-
tomorphometric and microcomputed tomography ana-
lyses of transiliac biopsies (6). Studies investigating bone
geometry using peripheral quantitative computed to-
mography (pQCT) have mainly been performed in pe-
diatric and adolescent populations. These studies generally
showed a smaller cortical area in children or adolescents
with T1DM vs controls (7–9), whereas the smaller tra-
becular area reported by some studies could not be con-
firmed in others (7, 9, 10). Although one longitudinal
study suggested that trabecular and cortical bone size
deficits in adolescent T1DMpatients persist over time (11),
data on cortical bone geometry in adult patients with
T1DM are lacking.
This study aimed to compare areal and volumetric
bone parameters, bone geometry, and possible mediators
thereof in adult individuals with T1DMand sex- and age-
matched controls. In addition, becauseT1DMis considereda
condition of impaired bone turnover, bone turnover
markers were measured and related to bone density
and geometry.
Methods
Study population
Sixty-four adult patients with T1DM were recruited from
the outpatient clinic of the Endocrinology Department at the
Ghent University Hospital. Patients were eligible for inclusion
if they had a diagnosis of T1DM with a disease duration of at
least 7 years, and no known macrovascular disease. Data on
medication use, the presence of MVD, and glycated hemo-
globin (HbA1c) levels were extracted from the patient’s
electronic health record. Patients were classified as having
MVD if diabetic retinopathy (diagnosed by an ophthalmologist
based on retinal examination) and/or diabetic nephropathy
(urinary albumin/creatinine ratio .30 mg/g in two out of three
random voided urine samples) and/or diabetic neuropathy
(based on electromyography) were present. Mean HbA1c over
the last 5 years was calculated if at least three measurements
were available (n = 63; mean number of available measure-
ments, 9.7 6 3.0), with HbA1c variability defined as the
standard deviation (SD) of these measurements. Immediately
after the study visit, patients started wearing a continuous
glucose monitoring (CGM) device (DexCom G4 Platinum;
DexCom, San Diego, CA) from which short-term glycemic
variability (defined as the SD of glucose levels over a 7-day
period) was evaluated. During this 7-day period, patients were
asked to maintain their normal activity pattern and were
blinded to the results of the CGM. Patients were matched based
on age and sex with 63 nondiabetic control subjects. Male
controls were selected from a previously studied male sibling-
pair cohort, recruited from semirural communities around
Ghent, Belgium (12). Female controls were selected from a
previously studied female control cohort, recruited by poster
campaign at the Ghent University Hospital, on its Web site, and
in schools (13). Exclusion criteria for the control subjects were
defined as illnesses or medication use known to affect body
composition, hormone levels, or bone metabolism. In women, a
history of menstrual irregularities, hirsutism, or polycystic
ovarian syndrome were additional exclusion criteria. The study
protocol was approved by the ethical committee of the Ghent
University Hospital, and written informed consent was ob-
tained from all participants.
Anthropometry, areal bone parameters, and
whole-body soft tissue composition
Body weight was measured to the nearest 0.1 kg in light
indoor clothing without shoes. Standing height was measured
to the nearest 0.1 cm using a wall-mounted Harpenden
stadiometer (Holtain Ltd., Crymuch, UK). Areal bone pa-
rameters [including bone mineral content (BMC), bone area,
and aBMD at the whole body minus head, lumbar spine,
femoral neck, and total hip region] and whole-body soft
tissue composition (including total body lean and fat mass)
were measured using DXA with a Hologic QDR-4500A
device (software version 11.2.1; Hologic, Bedford, MA).
The coefficients of variation (CVs) for both spine and whole-
body calibration phantoms were ,1% for aBMD and ,3%
for BMC as calculated from daily and weekly phantom
measurements, respectively.
Volumetric bone parameters, bone geometry, and
regional soft tissue composition
Volumetric bone parameters, bone geometry, and regional
soft tissue composition were determined at the radius using a
pQCT device (XCT-2000; Stratec Medizintechnik, Pforzheim,
Germany). Trabecular bone area, BMC, and volumetric bone
mineral density (vBMD) were measured at the distal radius (4%
of bone length from the distal end); cortical bone area, BMC,
and vBMD as well as bone geometry and regional soft tissue
composition were measured at the radial shaft (66% of bone
length from the distal end). Imaging and the calculation of
numerical values were performed using the manufacturer’s
software package (version 5.4). The cross-sectional area (CSA)
of the radius was determined after detecting the outer bone
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contour at a threshold of 280 mg/cm3. By default, 55% of this
bone CSA was peeled off to separate trabecular bone from
the cortical shell at the distal radius. For determining cortical
vBMD, the threshold was set at 710 mg/cm3; for trabecular
bone, the threshold was set at 180 mg/cm3. Periosteal and
endosteal circumference and cortical thickness were esti-
mated using a circular ring model, with cortical thickness as
the difference between the outer and inner radius. The
cortical over total bone area ratio (%) was calculated as
cortical bone area divided by total bone area. Polar strength-
strain index was calculated as previously described (14).
Muscle and fat CSA surrounding the bone were estimated
using a threshold below water equivalent linear attenuation
set at 0.22/cm. The cortical bone over muscle area ratio (%)
was calculated as cortical bone area divided by muscle CSA.
Bone marrow density was estimated using a threshold set at
100 mg/cm3, with lower values indicating a higher marrow
fat content. The CV for the calibration phantomwas,1% as
calculated from daily phantom measurements.
Biochemical measurements
Venous blood samples were obtained after an overnight
fast. Serum samples were stored at 280° until batch analysis.
C-terminal telopeptide of type 1 collagen (CTX), procollagen
type 1 N-terminal propeptide (P1NP), intact parathyroid
hormone (PTH), and 25-hydroxyvitamin D [25(OH)D] were
measured using electrochemiluminescence immunoassays
(Roche Diagnostics, Mannheim, Germany). Intra- and inter-
assay CVs were 0.7% and 8.5% at 183 mg/L for P1NP, and
1.1% and 3.8% at 1.15 mg/L for CTX.
Statistics
Descriptive statistics are expressed as mean 6 SD or
median (first to third quartile) if criteria for normality were
not fulfilled. Visual inspection of histograms and quantile-
quantile plots and Shapiro-Wilk tests were performed to
assess normality. Nonnormally distributed variables were
log-transformed to meet required model assumptions. Dif-
ferences in general characteristics between subjects with
T1DM and their matched controls were evaluated using
paired t tests (for age, height, weight, and BMI), Wilcoxon
matched-pairs signed-rank test (for alcohol intake), or
McNemar test (for smoking behavior; categorized as current
smoker vs nonsmoker). Unless stated otherwise, between-
group differences in bone variables were assessed using
multivariate linear regression analysis with adjustment for
age, height, weight, and sex. To investigate whether between-
group differences in bone variables differed according to sex,
an interaction term between sex and health status (T1DM or
control) was added to the models. In case of a statistically
significant interaction, age-, height-, and weight-adjusted
between-group differences were evaluated separately for
men and women. Women taking oral contraceptives (n = 7)
were excluded from analyses involving bone turnovermarkers.
In subjects with T1DM, associations between disease char-
acteristics and bone variables were assessed using multi-
variate linear regression analysis with adjustment for age,
height, weight, and sex. All analyses were performed using
SPSS version 24.0 (IBM Corp., Armonk, NY). P values were
considered significant at values ,0.05; all tests were two-
tailed.
Results
Characteristics of the study population
General characteristics of the study population and
disease-related parameters of the subjects with T1DMare
summarized in Table 1. Both the T1DM and control
groups included 38 men, accounting for 59.8% of the
study population. Participants were between 22 and
60 years old, and no differences in height, weight, or BMI
were observed between subjects with T1DM and their
respective controls. Alcohol intake was lower [2 (1 to 6)
vs 5 (2 to 14) units per week, P = 0.002], whereas the
number of current smokers was nonsignificantly higher
(25.0% vs 12.7%, P = 0.078) in the T1DM group. Seven
premenopausal women with T1DM used oral contra-
ceptives compared with none of the control women. In
the T1DM group, six participants used a vitamin D and
two used a calcium supplement. Age at diagnosis of
T1DM ranged from 1 to 41 years; 39 subjects (61.9%)
were #20 years at diagnosis. Current metabolic control
ranged from good to poor with HbA1c values between
6.4% and 9.9%. Thirty-seven patients (57.8%) were
classified as having MVD, including 27 (42.2%) with
diabetic retinopathy, 22 (34.4%) with nephropathy, and
14 (21.1%) with neuropathy. None of the participants
had an estimated glomerular filtration rate,60 mL/min/
1.73 m2.
Areal and volumetric bone parameters and
bone geometry
As shown in Table 2, subjects with T1DM presented
with lower BMC and aBMD at the total body
(D = 29.9% and 29.3%, respectively), the femoral neck
(D = 28.7% and 28.5%), and the total hip (D = 25.0%
and 25.3%). In addition, T1DM was associated with a
0.9% smaller bone area at the total body, whereas no
differences in DXA measurements were observed at the
spine. For BMCand aBMDat the total body, a significant
interaction existed between health status and sex (P =
0.002 and P , 0.001, respectively), with greater bone
deficits in men (D = 212.5% for BMC and 213.2% for
aBMD, both P, 0.001) than in women (D =28.2%, P =
0.001 for BMC; D = 24.6%, P = 0.006 for aBMD) with
T1DM compared with controls. No interactions between
health status and sex were observed at the femoral neck,
total hip, or spine.
Differences in pQCT-derived volumetric and geo-
metric bone parameters in subjects with vs without
T1DMare summarized in Table 3 and Fig. 1. At the distal
radius, subjects with T1DM presented with a 10.4%
larger trabecular area but 8.8% lower trabecular vBMD
compared with controls. A significant interaction be-
tween health status and sex was observed for trabecular
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area (P = 0.039), with a larger area in men (D = 13.9%,
P, 0.001) but not women (D = 3.3%, P = 0.482) with vs
without T1DM. At the radial shaft, cortical vBMD was
2.1% higher, whereas total vBMD was 5.0% lower in
subjects with T1DM. Furthermore, T1DM was associ-
ated with a similar periosteal but 6.1% larger endosteal
circumference, a 5.6% smaller cortical thickness, and a
6.0% lower cortical over total bone area ratio, with no
significant interactions between health status and sex.
All between-group differences in DXA- and pQCT-
derived bone parameters remained significant after ad-
ditional adjustment for alcohol intake and smoking status,
as well as after the exclusion of six postmenopausal women
(data not shown).
Bone turnover markers
P1NP, CTX, PTH, and 25(OH)D levels were not
different in subjects with T1DM vs controls when the
whole study population was considered (Table 1);
however, significant interactions between health status
and sex were observed for CTX, PTH, and 25(OH)D (P =
0.001, P = 0.018, and P = 0.019, respectively). Further
analysis showed that CTX and 25(OH)D levels were
lower and PTH levels were higher in male T1DMpatients
compared with controls (D = 227.6%, P = 0.023 for
CTX; D =224.0%, P = 0.009 for 25(OH)D; D = 27.9%,
P = 0.017 for PTH), whereas female T1DM patients
presented with higher CTX (D = 58.3%, P = 0.028), but
no differences in 25(OH)D or PTH (P = 0.126 and P =
0.341, respectively). After additional adjustment for al-
cohol intake and smoking status, the difference in PTH
levels in men remained significant (P = 0.003), whereas
other results were somewhat attenuated (CTX: P = 0.056
in men and P = 0.061 in women; 25(OH)D in men: P =
0.077). Additional adjustment for bone turnover, PTH,
and 25(OH)D levels did not affect the previously de-
scribed differences in areal and volumetric bone pa-
rameters and bone geometry between subjects with
T1DM and controls (data not shown).
Soft tissue composition and bone marrow density
Neither total body lean mass (56.1 6 11.5 vs 53.7 6
9.6 kg, P = 0.707), fat mass (17.26 6.6 vs 18.06 6.4 kg,
P = 0.733), or percentage of fat mass (24.0% 6 8.2% vs
25.8% 6 8.3%, P = 0.198), nor muscle CSA (3705.9 6
959 vs 37416 916mm2,P =0.529) or fat CSA (11586 564
Table 1. General Characteristics of the Study Population, Bone Turnover Markers, and Disease-Related
Parameters in Subjects With T1DM
All Men Women
T1DM (n = 64) Control (n = 63) P T1DM (n = 38) Control (n = 38) T1DM (n = 26) Control (n = 25)
Age, y 41.1 6 8.1 41.4 6 8.4 0.005 41.4 6 8.5 42.2 6 9.3 40.6 6 7.6 40.3 6 6.8
Height, cm 173.5 6 9.8 172.5 6 8.3 0.304 179.2 6 7.1 177.0 6 6.1 165.3 6 7.0 165.7 6 6.4
Weight, kg 76.2 6 13.4 75.9 6 10.7 0.946 81.1 6 12.3 79.5 6 9.5 68.9 6 11.8 70.4 6 10.2
BMI, kg/m2 25.20 6 3.34 25.49 6 3.11 0.421 25.22 6 3.08 25.42 6 3.18 25.19 6 3.75 25.61 6 3.07
Age at disease
onset, y
18.6 6 9.7 — n/a 18.9 6 9.1 — 18.2 6 10.6 —
Disease duration, y 22.1 6 8.7 — n/a 21.9 6 8.4 — 22.4 6 9.3 —
HbA1c, % 7.71 6 0.71 — n/a 7.82 6 0.76 — 7.54 6 0.60 —
Mean glucose level
during CGM,
mg/dL
160 6 31 — n/a 163 6 33 — 155 6 28 —
Glycemic variability
during CGM,
mg/dL
71.4 6 12.2 — n/a 69.9 6 11.5 — 73.5 6 12.9 —
Mean HbA1c over
last 5 y, %
7.9 6 0.7 — n/a 8.0 6 0.7 — 7.7 6 0.5 —
HbA1c variability
over last 5 y, %
0.43 6 0.27 — n/a 0.41 6 0.27 — 0.46 6 0.28 —
P1NP, mg/L 38.7 (28.9–48.1) 42.6 (35.5–49.5) 0.218 36.3 (29.3–47.7) 42.6 (34.6–47.9) 42.3 (29.0–47.9) 42.8 (36.2–51.2)
CTX, mg/L 0.20 (0.16–0.25) 0.23 (0.12–0.31) 0.940 0.21 (0.16–0.26) 0.29 (0.23–0.34)a 0.19 (0.16–0.24) 0.12 (0.10–0.16)a
25(OH)D, ng/mL 27.1 (21.2–39.4) 29.8 (21.5–35.9) 0.213 23.8 (19.9–32.7) 31.3 (24.9–36.0)b 34.0 (24.6–42.8) 25.3 (19.3–35.9)
PTH, ng/L 34.1 (27.4–42.8) 30.3 (24.7–39.2) 0.187 34.4 (27.6–39.9) 26.9 (20.9–34.1)a 34.9 (22.7–46.8) 35.7 (29.0–44.9)
Data are expressed as mean 6 SD or median (first to third quartile). P values are derived from paired t tests (for age, height, weight, and BMI) or from
multivariate regression analysis with adjustment for age, height, weight, and sex (for log-transformed bone turnover markers).
Abbreviations: BMI, body mass index; n/a, not applicable.
aP , 0.050 for sex-specific age-, height-, and weight-adjusted differences in subjects with vs without T1DM (only evaluated in case of statistically
significant interaction between sex and health status).
bP , 0.010 for sex-specific age-, height-, and weight-adjusted differences in subjects with vs without T1DM (only evaluated in case of statistically
significant interaction between sex and health status).
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vs 1123 6 465 mm2, P = 0.601) were different in subjects
with vs without T1DM. No interactions were observed be-
tween health status and sex. Furthermore, we observed no
difference in cortical bone over muscle area ratio (2.45% 6
0.44% vs 2.47% 6 0.40%, P = 0.793).
Subjects with T1DM presented with 33.3% lower
bone marrow density compared with controls (19.8 6
7.8 vs 29.76 9.6 mg/cm3, P, 0.001). In all participants,
marrow density was positively associated with cortical
thickness and cortical over total bone area ratio (b = 0.20,
P = 0.017 and b = 0.27, P = 0.021, respectively), and
inversely with endosteal circumference (b = 20.19, P =
0.021). Moreover, after additional adjustment for bone
marrow density, the differences in endosteal circumfer-
ence, cortical thickness, and cortical over total bone area
ratio between subjects with T1DM and controls lost
Table 2. Differences in DXA-Derived Areal Bone Parameters Between Subjects With T1DM and Controls
All Men Women
T1DM Control P T1DM Control T1DM Control
Whole body
Area, cm2 1961.16 228.0 1969.96 177.3 0.002 2081.96 171.1 2070.8 6 125.8 1766.96 165.9 1848.8 6 153.6
BMC, g 1819.86 360.6 2005.76 387.8 ,0.001 1994.06 322.5 2279.36 275.1a 1539.46 212.9 1677.36 202.6b
aBMD, g/cm2 0.919 6 0.088 1.012 6 0.119 ,0.001 0.953 6 0.090 1.098 6 0.087a 0.867 6 0.056 0.909 6 0.052b
Total hip
Area, cm2 41.1 6 7.2 40.9 6 6.5 0.775 45.5 6 5.2 45.0 6 4.5 34.8 6 4.4 34.7 6 3.4
BMC, g 39.6 6 10.4 41.7 6 10.0 0.022 44.8 6 9.6 47.2 6 8.7 32.1 6 5.8 33.2 6 4.3
aBMD, g/cm2 0.956 6 0.140 1.010 6 0.128 0.006 0.980 6 0.151 1.044 6 0.135 0.922 6 0.114 0.957 6 0.099
Femoral neck
Area, cm2 5.50 6 0.54 5.57 6 0.62 0.143 5.84 6 0.32 5.95 6 0.45 5.01 6 0.39 4.99 6 0.30
BMC, g 4.31 6 0.72 4.72 6 0.83 ,0.001 4.56 6 0.73 5.04 6 0.83 3.95 6 0.52 4.22 6 0.54
aBMD, g/cm2 0.776 6 0.143 0.848 6 0.123 0.001 0.782 6 0.124 0.848 6 0.138 0.767 6 0.169 0.847 6 0.099
Spine
Area, cm2 66.1 6 8.4 65.0 6 9.3 0.755 71.0 6 5.8 69.3 6 7.3 58.4 6 5.5 58.5 6 8.1
BMC, g 67.8 6 11.6 68.9 6 11.1 0.200 72.8 6 11.4 71.5 6 11.6 59.8 6 6.5 65.0 6 9.2
aBMD, g/cm2 1.025 6 0.106 1.054 6 0.117 0.094 1.024 6 0.118 1.032 6 0.126 1.026 6 0.087 1.087 6 0.095
Data are expressed as mean 6 SD. P values are derived from multivariate regression analysis with adjustment for age, height, weight, and sex.
aP , 0.001 for sex-specific age-, height-, and weight-adjusted differences in subjects with vs without T1DM (only evaluated in case of statistically
significant interaction between sex and health status).
bP , 0.010 for sex-specific age-, height-, and weight-adjusted differences in subjects with vs without T1DM (only evaluated in case of statistically
significant interaction between sex and health status).
Table 3. Differences in pQCT-Derived Volumetric Bone Parameters and Cortical Bone Geometry Between
Subjects With T1DM and Controls
All Men Women
T1DM Control P T1DM Control T1DM Control
Distal radius
Trabecular vBMD, mg/cm3 192 6 37 210 6 45 0.010 201 6 35 219 6 42 178 6 36 198 6 48
Trabecular BMC, mg/mm 35.6 6 10.9 35.2 6 8.7 0.844 42.1 6 10.1 39.5 6 7.5 27.0 6 7.3 28.6 6 5.9
Trabecular bone area, mm2 185.56 40.0 168.16 28.1 ,0.001 207.46 30.3 182.16 23.6a 151.86 28.0 146.96 20.2
Radial shaft
Total vBMD, mg/cm3 683 6 91 719 6 83 0.018 675 6 96 711 6 77 693.7 6 85 730 6 91
Cortical vBMD, mg/cm3 1136 6 49 1113 6 36 0.004 1128 6 54 1110 6 33 1148 6 39 1118 6 41
Cortical BMC, mg/mm 99.8 6 19.9 99.8 6 18.1 0.877 109.66 18.2 108.6 6 16.7 84.8 6 11.5 86.5 6 10.7
Cortical bone area, mm2 87.8 6 16.9 89.7 6 16.2 0.284 96.8 6 14.4 97.8 6 14.9 73.8 6 9.5 77.3 6 8.5
Cortical/total bone area ratio,% 50.3 6 8.0 53.5 6 6.9 0.014 50.2 6 8.7 53.6 6 6.7 50.5 6 6.9 53.5 6 7.5
Periosteal circumference, mm 47.1 6 5.5 46.0 6 4.6 0.115 49.7 6 4.9 48.0 6 4.2 43.1 6 3.9 42.8 6 3.2
Endosteal circumference, mm 33.3 6 6.1 31.4 6 4.8 0.030 35.2 6 6.3 32.8 6 4.7 30.3 6 4.6 29.2 6 4.3
Cortical thickness, mm 2.20 6 0.36 2.33 6 0.32 0.012 2.31 6 0.38 2.43 6 0.31 2.02 6 0.24 2.19 6 0.28
SSIp, mm3 357 6 100 338 6 101 0.165 412 6 81 394 6 88 273 6 60 255 6 47
Data are expressed as mean 6 SD. P values are derived from multivariate regression analysis with adjustment for age, height, weight, and sex.
Abbreviation: SSIp, polar strength-strain index.
aP , 0.001 for sex-specific age-, height-, and weight-adjusted differences in subjects with vs without T1DM (only evaluated in case of statistically
significant interaction between sex and health status).
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significance (P = 0.251, P = 0.136, and P = 0.258,
respectively).
Associations of bone parameters with
disease characteristics
Areal or volumetric bone parameters were not asso-
ciated with disease duration, age of disease onset, current
HbA1c, or the presence ofMVD (data not shown). Short-
term glycemic variability, mean HbA1c over the last
5 years, and HbA1c variability were inversely associated
with cortical area (b = 20.24, P = 0.008 for glycemic
variability; b =20.20, P = 0.030 for HbA1c; b =20.18,
P = 0.048 for HbA1c variability) and cortical BMC
(b =20.23, P = 0.021 for glycemic variability; b =20.19,
P = 0.053 for HbA1c; b = 20.19, P = 0.055 for HbA1c
variability). In addition, HbA1c variability was inversely
associated with total body BMC and aBMD (b = 20.15,
P = 0.039 and b = 20.23, P = 0.029, respectively).
Discussion
This study investigated cortical bone geometry using
pQCT in adult patients with T1DM. Our results indicate
that T1DM is associated with a cortical bone size deficit
at the radial shaft, characterized by a similar periosteal
but larger endosteal circumference, a smaller cortical
thickness, and a lower cortical over total bone area ratio
compared with a nondiabetic age- and sex-matched
population. In addition, we showed that individuals
with T1DMpresent with a larger trabecular area, a lower
trabecular but higher cortical vBMD at the radius, and a
lower aBMD at the total body, femoral neck, and total
hip. Whereas these differences could not be explained by
differences in body composition or current bone turnover
or mineral metabolism, patients with T1DM presented
with a higher bone marrow fat content. Furthermore,
although bone parameters in subjects with T1DM were
not associated with current metabolic control, disease
duration, age of disease onset, or MVD, a higher mean
HbA1c over the last 5 years as well as higher glycemic
variability were associated with a smaller cortical bone
area.
Few studies have investigated cortical bone geometry
in adult T1DM patients, with previous work mainly
focusing on pediatric and adolescent populations. In line
with our findings, these studies generally reported a
smaller cortical area in subjects with T1DM compared
with a reference population (7–9). Whereas this cortical
bone size deficit persisted over a 1-year period in a
longitudinal extension of one study (11), it normalized
over a 5-year period in another report (15). Only two
other studies have investigated bone geometry in adults
with T1DM, showing a cortical bone size deficit both at
the hip using central quantitative computed tomography
(16), and at the ultradistal radius using HR-pQCT (5).
The results of our study corroborate these findings, and
Figure 1. Relative differences in pQCT-derived volumetric and geometric bone parameters in subjects with T1DM vs controls (reference line). CI,
confidence interval.
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suggest that rather than reduced periosteal apposition
(i.e., modeling), increased endosteal resorption (i.e.,
remodeling) might be the main cause of this cortical bone
size deficit. Data on trabecular bone geometry in subjects
with T1DM have been more conflicting, with studies in
children showing a similar (7) or smaller trabecular area
(9–11), whereas we and others observed a larger tra-
becular area in adults with T1DM compared with con-
trols (5). The mechanisms behind these discrepancies are
unclear; however, it has been hypothesized that the in-
crease in trabecular area might serve as a mechanism to
offset microstructural changes in the trabecular bone
tissue (4, 5).
Our findings concerningDXA-measured aBMD largely
corroborate the results of two meta-analyses (3, 17);
however, we did not find a difference in aBMD at the
spine. This may at least in part be explained by the fact
that a substantial number of subjects in our study had
diabetic nephropathy, which is often associated with
falsely elevated aBMD measurements at the spine be-
cause of aortic calcifications. Measuring trabecular
bone mineral density (BMD) at peripheral sites might be
more appropriate in patients with T1DM, and in
agreement with previous studies, we indeed observed a
lower trabecular vBMD in subjects with T1DM vs
controls (5, 7, 9, 18, 19). In line with our findings,
cortical vBMDhas generally been shown to be preserved
in children with T1DM (7–9, 11, 15); however, lower
values were reported in one other study in adults (5).
Nonetheless, the latter study was performed using HR-
pQCT at the ultradistal radius, which is mainly a tra-
becular bone site and therefore less suitable to assess
cortical bone parameters.
One possible explanation for the bone size and/or
density deficits associated with T1DM is that these pa-
tients have an altered bone turnover and/or mineral
metabolism. Several studies have shown that T1DM is
associated with a state of low bone turnover, with de-
creased levels of bone resorption as well as formation
markers (4, 5, 20–24). In our study population, however,
we only observed somewhat lower CTX levels in men,
whereas P1NP levels were not different in subjects with vs
without T1DM. Furthermore, our finding of increased
endosteal circumference rather contrasts with a putative
decrease in local bone turnover, suggesting that other
factors may underlie the observed cortical bone size
deficit in T1DM.
T1DM is also characterized by alterations in the
growth hormone/insulinlike growth factor 1 (IGF-1) axis,
which may be another contributing factor to the bone
phenotype observed in these patients. First, IGF-1 is an
important regulator of bone mass acquisition and
maintenance (25). Although the current study did not
investigate IGF-1 levels, other authors have indeed re-
ported lower levels of IGF-1 in patients with T1DM, as
well as positive associations of IGF-1 and its binding
proteins with BMD, cortical bone area, and trabecular
microstructure (4, 8, 16, 19). Second, growth hormone
and IGF-1 are involved in the regulation of body com-
position (26–28), which in turn importantly determines
bone health (29–32). Nonetheless, in agreement with
previous reports, we observed no differences in body
composition in subjects with vs without T1DM in the
current study (7, 15). Furthermore, we found no differ-
ences in the bone over muscle area ratio, indicating an
adequate adaptation of bone size to muscle size and
therefore a preserved muscle-bone relationship in pa-
tients with T1DM.
A third putative explanation for the bone size deficit
associated with T1DM involves the differentiation of
mesenchymal stem cells, which are the common pro-
genitors of adipocytes, osteoblasts, and chondroblasts
residing in the bone marrow. A reciprocal relationship
exists between adipogenesis and osteoblastogenesis, and
studies in nondiabetic populations have shown inverse
associations between bone marrow adiposity on the one
hand and bone size or density on the other (33–37).
Moreover, increased bone marrow adiposity has been
shown to be associated with a smaller cortical but not
total bone area, suggesting that the inverse association
between marrow adiposity and cortical bone size might
preferentially occur through increased endosteal expan-
sion (34–36). In line with experimental data demon-
strating increased bone marrow adiposity in T1DMmice
(38, 39), our T1DM population had lower pQCT-derived
bone marrow density values compared with controls.
Lower bone marrow density was moreover associated
with a larger endosteal circumference and a smaller
cortical thickness, and adjustment for marrow density
attenuated the differences in cortical bone geometry
between subjects with T1DM and controls. Thus, our
findings support a possible role of increased bone
marrow fat content in the development of the cortical
bone size differences associated with T1DM. Only two
other clinical studies have investigated bone marrow
adiposity in T1DM, with one study showing no dif-
ference in MRI-derived vertebral, femoral, or tibial
marrow adiposity (40), and another study showing a
nonsignificant trend toward higher vertebral marrow
adiposity in young T1DM women (4). Nonetheless,
these studies were hampered by small sample sizes, and
the possibility of increased marrow adiposity as a
contributor to the alterations in bone geometry in
T1DM merits further research.
To date, little consensus exists on the clinical de-
terminants of bone health in patients with T1DM.
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Meta-analyses have suggested an association of bone
turnover but not BMD with metabolic control, but no
associations with disease duration (3, 24). In line with
other studies, we observed no association between bone
geometry and disease duration, age of disease onset, or
current metabolic control (5, 8, 10, 11, 16). However,
we did observe inverse associations of cortical bone area
with short- and long-term glycemic variability, as re-
flected by CGM-derived glucose SD over a 7-day period
andHbA1c variability over the last 5 years. Although no
previous studies have included glycemic variability as a
possible clinical determinant of bone fragility in T1DM,
long-term fluctuations in metabolic control have been
shown to contribute to the development and/or progres-
sion of other micro- or macrovascular complications (41,
42). Our findings suggest that in parallel herewith, fluc-
tuations in long-termmetabolic controlmay also adversely
affect cortical bone size. Whereas recent studies have been
pointing toward the presence of MVD as a predictor of
deficits in trabecularmicroarchitecture (4, 5), we could not
confirm any association with cortical bone geometry.
Strengths of our study include the homogeneous
population of adult patients with relatively long-standing
T1DM, well-characterized in terms of metabolic control
and the presence ofMVD, aswell as the use of an age- and
sex-matched control group. Bone geometry was assessed
using state-of-the-art methods, with pQCT measure-
ments performed by an experienced study team to min-
imize measurement variation. Besides the cross-sectional
design of our study, which obviously does not allow for
drawing conclusions about causality, an important lim-
itation includes the lack of information on physical
activity. Nonetheless, the fact that we observed no dif-
ferences between subjects with T1DM and controls in
terms of body composition and muscle size suggests that
if any differences in physical activity were present, they
might not have been large enough to affect bone size
through effects on muscle mass. The lack of information
on sex steroid levels in all, and on age ofmenarche, parity,
and history of lactation in female participants represents
another limitation. Further, although a high level of
agreement between marrow fat quantification by
microcomputed tomography and histology analysis has
been shown in rats (43), the use of pQCT to examine bone
marrow density in humans has not been validated against
histomorphometry or MRI measurements, and our
findings regarding bone marrow density should therefore
be interpreted with caution. Although our sample size
was comparable with previous studies investigating bone
geometry in T1DM, it was not sufficient to evaluate
differences in men and women separately. Moreover, we
only performed bone geometry measurements at the
radius, and further studies are needed to investigate
whether bone geometry in T1DM is similarly affected in
both sexes as well as at other skeletal sites.
In conclusion, this study showed that in addition to the
known deficits in aBMD and trabecular vBMD, adult
patients with T1DM present with a cortical bone size
deficit, specifically characterized by a similar periosteal
but larger endosteal circumference compared with non-
diabetic subjects. These differences in bone geometry
cannot be explained by differences in body composition
or bone turnover, but may be associated with glycemic
variability as well as with a higher bone marrow fat
content in subjects with T1DM. Given the important
contribution of bone geometry to overall fracture risk, we
hypothesize that the cortical bone size deficit may con-
tribute to the increased fracture risk associated with
T1DM.
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